Genotyping of <i>CYP2C9</i> and <i>VKORC1</i> polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin-Reference-Cited by-同舟云学术

Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin

Published:2017 Issue:4 Volume:11 Page:198-205
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Arunkumar Ganesan¹,Vishnuprabu Durairajpandian¹²,Nupur Bitt³,Vidyasagaran Thiruvengadam³,Murugan Avaniyapuram Kannan⁴,Munirajan Arasambattu Kannan¹

Affiliation:

1. Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras

2. Centre for Cardiovascular Biology and Disease (CCBD), Institute for Stem Cell Biology & Regenerative Medicine (inStem), National Center for Biological Sciences (NCBS), GKVK

3. Department of Vascular Surgery, Madras Medical College and Rajiv Gandhi Government General Hospital

4. Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.jstage.jst.go.jp/article/ddt/11/4/11_2017.01031/_pdf

Reference29 articles.

1. 1. Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: A clinical review. J Blood Med. 2011; 2:59-69.

2. 2. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically III patients. Clin Ther. 2007; 29:2395-2405.

3. 3. Puehringer H, Loreth RM, Klose G, Schreyer B, Krugluger W, Schneider B, Oberkanins C. VKORC1 –1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol. 2010; 66:591-598.

4. 4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717-719.

5. 5. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10:139-150.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Warfarin Dose Maintenance Associated with CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) Gene Polymorphism in North Coastal Andhra Pradesh;The Open Biochemistry Journal;2024-08-29

2. Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients;Current Drug Metabolism;2021-10

3. THE EFFECTS OF GENETIC AND NON GENETIC FACTORS ON WARFARIN DOSE RESPONSE IN VENOUS THROMBOEMBOLISM;INDIAN JOURNAL OF APPLIED RESEARCH;2021-08-01

4. Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study;Current Drug Metabolism;2020-12-30

5. Value of VKORC1 (−1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population;Indian Heart Journal;2018-12